Drug Trial Radar · NCT06067490
A Phase I Study of RC1416 Injection
Last checked: Nov 19, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 29, 2023
Primary completion
May 14, 2024
Study completion May 14, 2024
Sponsor
- Lead sponsor
- Nanjing RegeneCore Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.
Conditions
- Healthy Volunteers
Interventions
RC1416(SAD)Drug
RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
Placebo(SAD)Drug
Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: up to 92 days
- Vital SignsTime frame: up to 92 days
- Laboratory TestsTime frame: up to 92 days
- ECGTime frame: up to 92 days
- Injection Site ReactionTime frame: up to 4 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.